Interim CFO (6/23 - 1/24)- Refined and shortened the Forecasting and Budgeting processes condensing budget by 2 months.- Realigned external bank cash holdings and paid down LOC saving $200K annually in interest.- Key leader of one staffing restructuring initiative.- Executive sponsor of NetSuite implementations.- M&A lead reviewing potential acquisition/divestiture opportunities.

CFO (6/21 – 1/23) Senior Vice President Finance/Corporate Controller– Lead the Finance, Accounting and Admin areas for publicly traded start-up clinical stage biopharmaceutical company focused on discovery and development of proprietary targeted biologic therapeutics for oncology- Recruited to stabilize and build out the Finance function including establishing proper SOX controls for the company, SEC reporting, and building of planning and forecasting process for the company- Led selection and implementation of several systems including Paycom, SAP & Concur- Present and discuss Financial information to MTEM Board of Directors- Extended interest only period of term loan to extend cash runway by full quarter

Lead the areas of Finance/Accounting, IT, Customer Service/Inside Sales/Sales Operations and Quality/Regulatory for over $200 million oral care CPG manufacturing company.- Represented SAI at company board meetings presenting financials and strategy.- Doubled operating income over 3 year period. Partnered with operations team to generate over $2 million in cost savings annually, improving Gross Profit by 1%. Ensure disciplined Sales & Marketing spending.- Negotiated and obtained financing for 3 new pieces of equipment that will generate $3 million of cogs improvement annually.- Responsible for annual audits, filing of taxes and banking relationships.- Created new valuation model for analysis and prioritization of R&D and Capital spending.

US Finance Site lead for all of R&D. Head of Global Development Operations (GDO) and Global Medical Organization (GMO) Finance. Coach team of 9 people.Responsible for all accounting, planning and reporting for all Takeda US R&DProvide Financial leadership in support of Procurement projects

Responsible for all Direct R&D Spending for Takeda Pharmaceuticals. Coach 7 people in three locations

Promoted from Director Finance in 2013 - Responsible for Analytics group of eight people for $1.8 billion not for profit health system made up of four hospitals. -Recruited to rebuild Cost Accounting Department. Redesigned entire activity based cost accounting system, which will enable reduction of 1 FTE and facilitate better analysis of procedure costs.-Created new efficiencies metrics report to analyze expenses as part of $9M cost reduction.-Finance lead on multiple care and cost transformation projects that will realize $150M in savings.-Finance lead for new Monthly Operating Review process with four hospital campuses-Responsible for analysis and booking of contractuals. Improved Net Revenue reporting

- Led Global Finance Business Intelligence project, a Cognos based reporting solution implemented as part of Global ERP project that is providing better transparency to global financial data at Baxter.- Led scoping project to re-engineer Planning & Forecasting process, member of implementation team that reduced plan cycle by 3 months and will reduce Long Range Plan cycle by 2 months.-Headed Global Finance Community Team in 2009 and increased Finance volunteerism and hours over 30%.-Led Long Range Financial Planning process for total company

- Created and led Long Range Financial Planning process for EMEA across all Global Business Units. - Led detailed sales, marketing, general and administrative spend analysis that was rolled out company wide for 2009 Operating Plan which prioritized over $2.5 Billion in global spending.- Provided Financial Support and modeling expertise for EMEA Business Development Group transactions which led to the formation of a Saudi Arabian manufacturing Joint Venture with Olayan Group as well as licensing and distribution agreements and a call option to purchase a company in South Africa. - Served on the Pan-European Strategy Team that identified Homecare as a priority area of focus for Region.

- Created and led a two week Long Range Financial Planning process for Global Bioscience.- Provided financial analysis and insight for R&D agreement signed with Nektar Therapeutics aimed at developing longer acting therapeutic forms of blood clotting proteins.- Led Division’s Sarbanes-Oxley compliance effort that reduced findings to zero.- Oversaw all Bioscience related SEC reporting and current updates of Investor Relations information

-Creation and implementation of monthly business planning process that forecasted the divisions’ sales and actual gross profit by product line.-Responsible for all business analysis including acquisitions/divestitures, capital investments, research and development projects and product line profitability.-Marketing responsibility for $30 million device business which we divested to a third party.-Responsible for Risk Sharing group and Vaporizer Marketing group, total staff of 17 people

Promoted from Manager in 2001. Responsibility for Business Development transactions such as acquisitions, divestitures, joint ventures and licensing agreements for $2 Billion dollar Renal division. Project Slingshot - Member of project team that closed the deal for Epoetin Omega. Member of negotiation team that helped set negotiation strategy and negotiated the deal. Helped lead and coordinate due diligence efforts. Althin Acquisition - Member of project team in $135 million dollar acquisition of Althin Medical AB. Althin Biopharm JV Acquisition - Co-negotiator on buyout of Axcan's (our Canadian joint-venture partner) interest in a $12 million dollar concentrate business. Helped set negotiation strategy and determined price to pay. Helped define Renal Strategy as part of team in 2001 analyzing strategic alternatives to pursue.

Consolidated and analyzed Operating Plan, Forecasts, and Strategic Plan for Baxter International, a medical products company with sales at the time of over six billion dollars.Coordinated the submission, requirements, and timing of Forecast, Plan, and Strategic Plan company wide.Worked with McKinsey consultants on valuation of Baxter using DCF modeling.Prepared financial presentations and reviewed analysis of acquisitions/divestitures and capital expenditures before they went before the Finance Committee of Baxter's Board of Directors.

Involved in consolidation, preparation and analysis of financial statements for the Biotech group with sales at the time of over one billion dollars.

Hyperion Administrator Designed, implemented, and provided training for the Hyperion Consolidation system for all reporting sites in 7 countries, for a leading supplier of automotive components with sales of over one billion dollars.Jim Beam Brands

Promoted from Accountant in 1994. Worked in financial reporting department of the largest American owned distiller. Involved in preparation and analysis of monthly financial package. Involved in analysis of sales/profitability and budgeting/forecasting for the Western Sales region.